Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3.

The thiazide diuretic chlorothiazide is poorly metabolized, and is predominantly excreted via the kidneys. We have previously shown that chlorothiazide is transported by ATP-binding cassette transporter G2, suggesting a potential role for this transporter in apical efflux of chlorothiazide in the kidney. However, because of the poor passive permeability of the drug, it is likely that uptake transporters on the basolateral membrane are also involved to facilitate vectorial transport in the renal proximal tubule. Two suggested candidate transporters for this role are the human organic anion transporters, OAT1 and OAT3. By using mammalian cells stably expressing these transporters, we have demonstrated OAT1- and OAT3-dependent uptake of chlorothiazide with Michaelis constant values of 14.5 and 37.6 µM, respectively. Furthermore, we have found that probenecid, furosemide, and diclofenac inhibit chlorothiazide transport by OAT1 and OAT3, of which the probenecide-mediated inhibition may be of clinical importance. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:1683-1687, 2013.

[1]  A. Greenberg Original articleDiuretic Complications , 2000 .

[2]  G. S. Gordon,et al.  Studies with chlorothiazide tagged with radioactive carbon (C14) in human beings. , 1960, Archives of internal medicine.

[3]  H. Saito,et al.  Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  H. Endou,et al.  Urate transport via human PAH transporter hOAT1 and its gene structure. , 2003, Kidney international.

[5]  Y. Kanai,et al.  Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. , 1999, American journal of physiology. Renal physiology.

[6]  Y. Kanai,et al.  Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.

[7]  Maristela Lika Onozato,et al.  Interactions of Human Organic Anion Transporters with Diuretics , 2004, Journal of Pharmacology and Experimental Therapeutics.

[8]  A. Straughn,et al.  Bioavailability of chlorothiazide tablets in humans. , 1979, Journal of pharmaceutical sciences.

[9]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[10]  F. Russel,et al.  The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.

[11]  G. Amidon,et al.  Pharmacokinetics of probenecid following oral doses to human volunteers. , 1982, Journal of pharmaceutical sciences.

[12]  F. Pea Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. , 2005, Contributions to nephrology.

[13]  Conrad C. Huang,et al.  The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. , 2006, American journal of physiology. Renal physiology.

[14]  M. Brandl,et al.  Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  G. Burckhardt,et al.  Human Organic Anion Transporter 3 (hOAT3) can Operate as an Exchanger and Mediate Secretory Urate Flux , 2003, Cellular Physiology and Biochemistry.

[16]  Franciska Erdő,et al.  ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. , 2012, Drug metabolism and pharmacokinetics.

[17]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[18]  P. Welling,et al.  Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. , 1982, Biopharmaceutics & drug disposition.

[19]  D. Goldfarb,et al.  Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. , 2007, The Journal of urology.

[20]  D. Brater Increase in diuretic effect of chlorothiazide by probenecid , 1978, Clinical pharmacology and therapeutics.